SCTV01E

SCTV01E is a tetravalent recombinant protein-based COVID-19 vaccine developed to provide broad protection against multiple SARS-CoV-2 variants, specifically Alpha, Beta, Delta, and Omicron BA.1. The vaccine consists of the trimeric spike extracellular domain (S-ECD) proteins from these four variants formulated with a squalene-based oil-in-water adjuvant (SCT-VA02B). It is designed to induce balanced and broad-spectrum neutralizing antibody responses as well as T cell immunity against both ancestral and emerging SARS-CoV-2 strains. Clinical trials have demonstrated that SCTV01E is safe, well tolerated, and highly immunogenic in adults and children. In phase 3 studies, it showed efficacy rates of approximately 80% in preventing symptomatic COVID-19 infection. The vaccine has been authorized for emergency use in China for adults aged 18 years and older[1][2][3][4][6].

Brand names

安诺能4

Other names

COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine